Your browser is no longer supported. Please, upgrade your browser.
Settings
CTIC CTI BioPharma Corp. daily Stock Chart
CTIC [NASD]
CTI BioPharma Corp.
Index- P/E- EPS (ttm)-2.89 Insider Own0.10% Shs Outstand27.02M Perf Week-6.34%
Market Cap139.69M Forward P/E- EPS next Y-2.70 Insider Trans0.00% Shs Float23.00M Perf Month1021.48%
Income-74.50M PEG- EPS next Q-0.65 Inst Own25.30% Short Float1.09% Perf Quarter1257.67%
Sales59.60M P/S2.34 EPS this Y-0.70% Inst Trans-0.13% Short Ratio0.29 Perf Half Y1336.11%
Book/sh0.64 P/B8.08 EPS next Y-38.50% ROA-67.40% Target Price3.75 Perf Year349.57%
Cash/sh2.28 P/C2.27 EPS next 5Y- ROE-173.60% 52W Range0.25 - 6.48 Perf YTD1168.40%
Dividend- P/FCF- EPS past 5Y-24.70% ROI-107.50% 52W High-20.68% Beta0.97
Dividend %- Quick Ratio1.40 Sales past 5Y119.10% Gross Margin97.90% 52W Low1944.55% ATR0.47
Employees149 Current Ratio1.50 Sales Q/Q340.00% Oper. Margin- RSI (14)76.93 Volatility8.79% 8.87%
OptionableYes Debt/Eq1.18 EPS Q/Q43.70% Profit Margin- Rel Volume0.26 Prev Close5.17
ShortableNo LT Debt/Eq0.75 EarningsFeb 07 AMC Payout- Avg Volume856.38K Price5.14
Recom3.50 SMA2072.57% SMA50254.06% SMA200669.71% Volume12,294 Change-0.58%
Feb-10-16Downgrade WallachBeth Hold → Sell
Feb-10-16Downgrade Piper Jaffray Overweight → Neutral
Feb-10-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-09-15Downgrade WallachBeth Buy → Hold $4.50 → $1.60
Aug-05-14Upgrade WallachBeth Hold → Buy $4.50
Mar-19-14Initiated WallachBeth Hold $4.50
Nov-04-13Initiated HC Wainwright Buy $4
Jan-10-17 09:15AM  Latest Reports on Recent Market Movers: 3D Systems and CTI BioPharma Accesswire
Jan-09-17 06:07AM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan +20.42%
01:30AM  CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017 PR Newswire
Jan-06-17 10:05PM  CTI Biopharma stock revived after FDA ruling, reverse stock split at bizjournals.com +7.62%
Jan-05-17 04:23PM  CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders +12.34%
12:43PM  Why CTI BioPharma Corp. Stock Popped Today at Motley Fool
01:30AM  CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib PR Newswire
Jan-04-17 10:51AM  ETFs with exposure to CTI BioPharma Corp. : January 4, 2017
08:05AM  CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-US : January 4, 2017
Jan-03-17 07:03AM  Splits Calendar: CTI BioPharma splits before market open today (1:10 ratio) +864.18%
Dec-23-16 04:59PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Dec-21-16 05:31PM  CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders
Dec-13-16 12:41PM  ETFs with exposure to CTI BioPharma Corp. : December 13, 2016
Dec-11-16 08:08AM  Do Hedge Funds Love Manning and Napier Inc (MN)? at Insider Monkey
Dec-09-16 05:15PM  CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Dec-06-16 10:30AM  PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting PR Newswire +11.42%
Dec-02-16 12:04PM  ETFs with exposure to CTI BioPharma Corp. : December 2, 2016 +9.60%
Dec-01-16 04:01PM  CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium PR Newswire +5.48%
Nov-30-16 05:00PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
01:04PM  CTI BIOPHARMA CORP Financials
Nov-21-16 04:01PM  CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting PR Newswire
Nov-10-16 12:12PM  ETFs with exposure to CTI BioPharma Corp. : November 10, 2016
Nov-09-16 11:46AM  CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 +9.46%
Nov-08-16 04:18PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:16PM  CTI BioPharma reports 3Q loss
04:01PM  CTI BioPharma Reports Third Quarter 2016 Financial Results PR Newswire
Oct-31-16 04:52PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Oct-24-16 06:05AM  CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definiti
Oct-23-16 04:23PM  5 Biotech Penny Stocks Smart Money Is Piling On at Insider Monkey
Oct-03-16 06:09AM  CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
01:30AM  CTI BioPharma Announces Retirement Of President And CEO PR Newswire
Sep-29-16 04:48PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Sep-22-16 01:30AM  CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule PR Newswire
Sep-19-16 04:46PM  CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Aug-31-16 05:28PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Aug-30-16 10:05AM  CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Aug-29-16 01:35PM  CTI BioPharma Meets One Of Two Endpoints In Phase 3 Trial +14.86%
06:00AM  CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis PR Newswire
Aug-04-16 06:09PM  CTI BioPharma reports 2Q loss
04:25PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:01PM  CTI BioPharma Reports Second Quarter 2016 Financial Results PR Newswire
Jul-28-16 04:43PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Jul-20-16 12:18PM  ETFs with exposure to CTI BioPharma Corp. : July 20, 2016
Jun-30-16 04:47PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan -6.87%
Jun-27-16 03:22PM  ETFs with exposure to CTI BioPharma Corp. : June 27, 2016 -15.14%
Jun-10-16 08:32AM  Surging Earnings Estimates Signal Good News for CTI BioPharma (CTIC)
Jun-08-16 08:08AM  Should CTI BioPharma (CTIC) Be On Your Radar Now?
Jun-07-16 01:30AM  Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting PR Newswire
Jun-03-16 03:15PM  ETFs with exposure to CTI BioPharma Corp. : June 3, 2016
May-31-16 04:53PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
May-20-16 11:40AM  ETFs with exposure to CTI BioPharma Corp. : May 20, 2016
May-19-16 01:30PM  CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2016 By the Numbers
01:30AM  CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting PR Newswire
May-10-16 04:31PM  CTI BioPharma posts 1Q profit
04:27PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:01PM  CTI BioPharma Reports First Quarter 2016 Financial Results PR Newswire
Apr-29-16 04:06PM  CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of
Apr-28-16 05:02PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Apr-20-16 01:30AM  Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment PR Newswire +5.17%
Apr-18-16 06:02AM  CTI BIOPHARMA CORP Files SEC form 8-K, Other Events
Apr-13-16 01:30AM  CTI BioPharma Announces Presentations at the American Association of Cancer Research Annual Meeting PR Newswire +5.01%
Apr-08-16 06:30PM  SHAREHOLDER NOTICE: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of Important April 11, 2016 Deadline in Class Action CTIC GlobeNewswire
12:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CTI BioPharma Corp. of Class Action Lawsuit and Upcoming Deadline - CTIC Accesswire
11:21AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In CTI BioPharma Corp. To Contact The Firm Before Imminent Lead Plaintiff Deadline Accesswire
10:00AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CTI BioPharma Corp. (CTIC) and Lead Plaintiff Deadline: April 11, 2016 Accesswire
Apr-07-16 12:13PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action and a Lead Plaintiff Deadline of April 11, 2016 Business Wire -6.62%
Apr-06-16 10:30AM  April 11 Deadline Alert: GPM Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Lawsuit against CTI BioPharma Corp. and Encourages Investors to Contact the Firm Business Wire
05:45AM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against CTI BioPharma Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm Business Wire
Apr-05-16 02:53PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In CTI BioPharma Corp. To Contact The Firm Before Lead Plaintiff Deadline PR Newswire
01:49PM  IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against CTI BioPharma Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm Business Wire
Apr-04-16 10:47AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2016 -- CTIC Marketwired
Mar-31-16 04:38PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
02:24PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2016 CTIC GlobeNewswire
12:01PM  April 11 Deadline Alert: Law Offices of Howard G. Smith Reminds CTI BioPharma Corp. Investors of Upcoming Lead Plaintiff Deadline Business Wire
Mar-30-16 07:31PM  INVESTOR NOTICE: Lundin Law PC Announces Investigation of CTI BioPharma Corp. and Encourages Investors with Losses to Contact the Firm Business Wire
Mar-27-16 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CTI BioPharma Corp. of Class Action Lawsuit and Upcoming Deadline CTIC GlobeNewswire
Mar-24-16 06:30AM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Investigation of CTI BioPharma Corp. and Urges Investors with Losses to Contact the Firm Business Wire
Mar-23-16 04:10PM  CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers -5.81%
Mar-15-16 09:14AM  Why You Shouldn't Bet Against CTI BioPharma (CTIC) Stock +6.14%
Mar-14-16 04:34PM  CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure
Mar-11-16 04:14PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CTI BioPharma Corp. of Class Action Lawsuit and Upcoming Deadline - CTIC PR Newswire
Mar-10-16 03:42PM  Cohen Milstein Sellers & Toll PLLC Announces the Investigation of CTI BioPharma Corp. -- CTIC GlobeNewswire -5.74%
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CTI BioPharma Corp. (CTIC) and Lead Plaintiff Deadline: April 11, 2016 PR Newswire
Mar-07-16 05:32PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CTI BioPharma Corp. CTIC GlobeNewswire
04:32PM  CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers
Mar-02-16 09:35AM  Michael Castors Sio Capital Managements New Bets For This Quarter at Insider Monkey +9.49%
Feb-29-16 05:54PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan -13.98%
Feb-27-16 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in CTI BioPharma Corp. of Class Action Lawsuit and Upcoming Deadline CTIC GlobeNewswire
Feb-24-16 04:43PM  INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Claims Against CTI BioPharma Corp. and Strongly Encourages Investors to Contact the Firm Business Wire
Feb-23-16 07:47PM  Lifshitz & Miller Law Firm Announces Investigation of Cigna Corporation, CTI Biopharma Corp., G. Willi-Food International Ltd., MannKind Corporation, Navient Corporation, Primero Mining Corp., and Skullcandy, Inc. PR Newswire
10:30AM  The Law Offices of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. Investors Business Wire
Feb-22-16 05:51PM  STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of Important Deadline in Class Action CTIC Business Wire +9.82%
11:00AM  CTI BioPharma Corp. Earnings Analysis: 2015 By the Numbers
Feb-17-16 06:02AM  CTI BIOPHARMA CORP Files SEC form 10-K, Annual Report +19.75%
Feb-16-16 05:32PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against CTI BioPharma Corp. Marketwired +22.91%
05:17PM  CTI BioPharma reports 4Q loss
04:16PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:01PM  CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results PR Newswire
02:18PM  CTI BioPharma Corp. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire
Feb-13-16 10:15AM  4 BioPharma Movers That Cannot Be Ignored at 24/7 Wall St.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreements with the University of Vermont, S*BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIANCO JAMES APresident and CEOJun 24Sale0.3710,0003,6541,780,133Jun 24 06:16 PM
BIANCO JAMES APresident and CEOMay 27Sale0.4510,0004,4711,790,133May 27 05:34 PM
BIANCO JAMES APresident and CEOApr 29Sale0.5210,0005,1621,800,133Apr 29 04:47 PM
BIANCO JAMES APresident and CEOMar 28Sale0.4910,0004,9411,810,133Mar 30 05:16 PM
BIANCO JAMES APresident and CEOMar 21Sale0.55318,169174,8661,820,133Mar 23 06:17 PM
Plunkett MatthewEVP, Chief Business OfficerMar 04Sale0.5910,0005,904590,084Mar 04 06:30 PM
BIANCO JAMES APresident and CEOFeb 26Sale0.6310,0006,2942,138,302Feb 26 06:18 PM
Plunkett MatthewEVP, Chief Business OfficerFeb 04Sale1.1510,00011,539600,084Feb 05 05:10 PM
BIANCO JAMES APresident and CEOJan 29Sale1.2010,00012,0122,248,302Jan 29 05:41 PM
SINGER JACK WEVP, Chief Scientific OfficerJan 29Sale1.1815,00017,7301,054,992Jan 29 05:30 PM